HOXB13 mutations in a population-based, case-control study of prostate cancer.
HOXB13 mutations in a population-based, case-control study of prostate cancer.
复制标题
DOI：
10.1002/pros.22604
复制
发表时间：
2013-05
期刊：
影响因子：
2.8
通讯作者：
Ostrander, Elaine A.
中科院分区：
文献类型：
--
作者：
Stott-Miller, Marni;Karyadi, Danielle M.;Smith, Tiffany;Kwon, Erika M.;Kolb, Suzanne;Stanford, Janet L.;Ostrander, Elaine A.
Prostate cancer (PC) is the most frequently diagnosed non-skin malignancy in men in the Western world, yet few disease-associated mutations have been found. Recently, a low frequency recurring mutation in the HOXB13 gene was reported among both hereditary PC families and men from the general population. We determined the distribution and frequency of the G84E HOXB13 variant in 1,310 incipient PC cases and 1,259 age-mated controls from a population-based, case control study of PC. The G84E mutation was more frequent in cases than controls (1.3% versus 0.4%, respectively), and men with the HOXB13 G84E variant had a 3.3-fold higher relative risk of PC compared with noncarriers (95% CI, 1.21–8.96). There was a stronger association between the G84E variant and PC among men with no first-degree relative with PC (OR, 4.04; 95% CI, 1.12–14.51) compared to men with a family history of PC (OR, 1.49; 95% CI, 0.30–7.50; p=0.36 for interaction). We observed some evidence of higher risk estimates associated with the variant for men with higher versus lower Gleason score (OR, 4.13; 95% CI, 1.38–12.38 vs OR, 2.71; 95% CI, 0.88–8.30), and advanced versus local stage (OR, 4.47; 95% CI, 1.28–15.57 vs OR, 2.98; 95% CI, 1.04–8.49), however these differences were not statistically different. These results confirm the association of a rare HOXB13 mutation with PC in the general population and suggest that this variant may be associated with features of more aggressive disease.
登录
查看更多内容
DOI：
10.1158/1055-9965.epi-12-0495
发表时间：
2012-08
期刊：
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
影响因子：
--
作者：
Breyer JP;Avritt TG;McReynolds KM;Dupont WD;Smith JR
通讯作者：
Smith JR
影响因子：
11.2
作者：
Levin, Albert M.;Machiela, Nlitchell J.;Douglas, Julie A.
通讯作者：
Douglas, Julie A.
DOI：
10.1056/nejmoa1110000
发表时间：
2012-01-12
期刊：
The New England journal of medicine
影响因子：
--
作者：
Ewing CM;Ray AM;Lange EM;Zuhlke KA;Robbins CM;Tembe WD;Wiley KE;Isaacs SD;Johng D;Wang Y;Bizon C;Yan G;Gielzak M;Partin AW;Shanmugam V;Izatt T;Sinari S;Craig DW;Zheng SL;Walsh PC;Montie JE;Xu J;Carpten JD;Isaacs WB;Cooney KA
通讯作者：
Cooney KA
影响因子：
5
作者：
WHITTEMORE, AS;WU, AH;STAMEY, T
通讯作者：
STAMEY, T
DOI：
10.1016/j.juro.2009.08.026
发表时间：
2009-12
期刊：
The Journal of urology
影响因子：
--
作者：
Wright JL;Salinas CA;Lin DW;Kolb S;Koopmeiners J;Feng Z;Stanford JL
通讯作者：
Stanford JL